505 related articles for article (PubMed ID: 18534438)
21. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
22. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
23. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Kälebo P; Christiansen AV; Hantel S; Hettiarachchi R; Schnee J; Büller HR;
J Thromb Haemost; 2007 Nov; 5(11):2178-85. PubMed ID: 17764540
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
25. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
26. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
27. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Burness CB; McKeage K
Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
29. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
30. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Eriksson BI; Dahl OE; Rosencher N; Clemens A; Hantel S; Kurth AA
Thromb Res; 2012 Dec; 130(6):871-6. PubMed ID: 22995531
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
33. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
35. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
36. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
37. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
[TBL] [Abstract][Full Text] [Related]
40. Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?
Hull R
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():5S-8S. PubMed ID: 19706619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
